文献速递临床试验与 GCP流行病学与生物统计

幽门螺杆菌根除后长期低剂量阿司匹林预防胃癌的有效性:Ardabil胃癌随机安慰剂对照预防试验(AGCPT)的研究设计与原理

Effectiveness of long-term low-dose aspirin in the prevention of gastric cancer after Helicobacter pylori eradication: study design and rationale of Ardabil gastric cancer randomized placebo-controlled prevention trial (AGCPT).
PubMed 文献 · Trials · 2024-09-19

AGCPT是一项前瞻性人群双盲随机安慰剂对照试验,目标样本为伊朗Ardabil省35至70岁男女共21000人,先行幽门螺杆菌粪便抗原检测并根除治疗,转阴者随机接受每日口服81毫克肠溶阿司匹林或安慰剂,平均随访10年,比较两组胃癌累积发病率和死亡率。

要点

  • 研究对象为幽门螺杆菌根除后人群,随机分组比较阿司匹林与安慰剂。
  • 干预为每日口服81毫克肠溶阿司匹林片,对照为安慰剂。
  • 主要评价指标为胃癌累积发病率和死亡率,平均随访10年。

核心结论

  • 阿司匹林除预防心血管事件等疾病外,可能预防胃癌发病和死亡,AGCPT将比较两组胃癌累积发病率和死亡率的差异。
  • 研究结果可能帮助政策制定者和研究者更新胃癌预防策略。

研究设计与样本

  • AGCPT为前瞻性人群双盲随机安慰剂对照临床试验,目标样本为伊朗Ardabil省35至70岁男女共21000人。
  • 所有合格参与者先以幽门螺杆菌粪便抗原检测筛查感染,阳性者接受标准化根除治疗。
  • 检测阴性者及阳性且后续根除确认试验阳性者进入干预阶段,采用置换平衡区组随机分为每日口服81毫克肠溶阿司匹林片组或安慰剂组。
  • 受试者平均随访10年,评价胃癌发病率和死亡率。
  • 试验在伊朗临床试验注册中心注册,注册号IRCT201105082032N3,注册日期2017年4月21日。

关键数值与推荐

  • 干预组每日口服81毫克肠溶阿司匹林片,对照组为安慰剂。
  • 目标样本量为21000名35至70岁参与者,平均随访10年。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In addition to Helicobacter pylori (H. pylori) infection eradication, some medications, including aspirin, metformin, and statins, have been suggested to have protective effects against gastric cancer (GC) development in observational studies. We launched the Ardabil gastric cancer randomized placebo-controlled prevention trial (AGCPT) to evaluate the effectiveness of long-term low-dose aspirin use for the prevention of development and mortality of GC after H. pylori eradication. METHODS/DESIGN: AGCPT is a prospective population-based double-blind, randomized clinical trial. The study sample was targeted at 21,000 participants aged from 35 to 70 years old, both sexes, in Ardabil, a province in northwest Iran with relatively high rates of GC incidence and mortality. All eligible participants were initially tested for H. pylori infection using a H. pylori stool antigen test. Participants with positive tests undergo H. pylori eradication by standard treatment regimens. All participants with a negative test and those with a positive test with a subsequent confirmed H. pylori eradication test were entered into the intervention phase. In the intervention phase, participants were allocated randomly into either the treatment (daily oral consumption of 81 mg enteric-coated aspirin tablets) arm or the control (placebo) arm using permuted balanced blocks. Subjects will be followed for an average period of 10 years to evaluate the incidence and mortality rates of GC. DISCUSSION: In addition to preventing other diseases like cardiovascular events, aspirin may prevent GC incidence and mortality. AGCPT will investigate the difference between the two study arms in the proportion of the cumulative incidence and mortality rates of GC. The study's results may help policymakers and researchers update the strategies for GC prevention. TRIAL REGISTRATION: This trial with the registry name of "The effect of Low-dose Aspirin in the Prevention of Gastric Cancer" was registered in the Iranian Registry of Clinical Trials, IRCT.ir, under the identifier IRCT201105082032N3. Registered on April 21, 2017.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Pourfarzi F, Rashidi MM, Yazdanbod A, et al. Effectiveness of long-term low-dose aspirin in the prevention of gastric cancer after Helicobacter pylori eradication: study design and rationale of Ardabil gastric cancer randomized placebo-controlled prevention trial (AGCPT). Trials. 2024. PMID: 39300505. doi:10.1186/s13063-024-08455-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。